In thislarge multicenter RCT of over 1500 cancer patients receiving chemotherapy through central venous catheters, they were randomized to fixed dose warfarin (1mg/day), dose adjusted warfarin(INR 1.5-2), or no warfarin. There was no difference in the groups in either catheter or non-catheter thrombosis. There is no role in cancer patients for warfarin in central venous catheter thrombosis prevention (abstract).
Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.